William Wallace: Hidden Vitamin B12 Deficiency and Better Testing Methods
William Wallace, Co-Founder and Chief Scientific Officer at Supplement Success Solutions, shared a post on X about a recent article by Ralph Carme, published in The American Journal of Clinical Nutrition, adding:
“Your B12 test measures two things and cannot distinguish between them.
Seventy to eighty percent of circulating vitamin B12 is bound to haptocorrin. The liver clears this fraction, and it never reaches the cells.
Twenty to thirty percent is bound to transcobalamin. This is the biologically active fraction that is actually delivered to tissues.
Clinicians refer to it as holo transcobalamin.
Standard serum vitamin B12 tests add both fractions together. A result that appears ‘normal’ can still mask a cellular deficiency, and these
tests miss approximately twenty-five to thirty percent of true deficiency cases.
The better tests are:
- Holo transcobalamin, which directly measures the active fraction
- Methylmalonic acid, which rises only when cellular vitamin B12 is truly insufficient and is considered a functional gold standard
- Homocysteine, which also rises in deficiency but is less specific because it can also increase with low folate, low vitamin B6, mthfr variants, kidney issues, aging. Less specific.
Who should care: adults over sixty years of age, long-term metformin users (ten to thirty percent develop deficiency), proton
pump inhibitor users, vegetarians and vegans, and anyone with unexplained fatigue, neuropathy, cognitive changes, or macrocytic anemia.
If vitamin B12 is reported as normal but symptoms do not match, it is reasonable to request holo transcobalamin and methylmalonic acid
testing.”
Title: Biomarkers of cobalamin (vitamin B-12) status in the epidemiologic setting: a critical overview of context, applications, and performance characteristics of cobalamin, methylmalonic acid, and holotranscobalamin II
Authors: Ralph Carme
Stay updated with Hemostasis Today.
-
Sep 23, 2026, 10:30Michael Angers: Advancing Transfusion Safety Through Smarter Laboratory Workflows
-
Sep 23, 2026, 07:28Isabelle Grenier-Pleau: Targeting Von Willebrand Disease to Transform Women’s Health
-
Sep 23, 2026, 07:07Wolfgang Miesbach: Mechanisms of Liver Injury After Hemophilia A Gene Therapy
-
Sep 23, 2026, 06:24Nicolas Gendron: Everolimus and Venous Thromboembolic Risk in Kidney Transplantation
-
Sep 23, 2026, 06:07Hoori Shahwar: Cerebral Venous Sinus Thrombosis Diagnosis and Management
-
Sep 23, 2026, 06:06Advancing Hemophilia Care and Patient Advocacy in Bangladesh – World Federation of Hemophilia
-
Sep 23, 2026, 05:54Bringing the Global Thrombosis and Haemostasis Community Together in 2027 – ISTH
-
Sep 23, 2026, 04:34David Akande: When Sickle Cell Crises Have No Clear Trigger
-
Sep 23, 2026, 04:13Jean Connors: Safety of Heparin Re-Exposure in Patients with Remote HIT